Cargando…

Body‐weight‐independent glucose‐lowering effect of the β3‐adrenergic receptor agonist mirabegron in humans

Detalles Bibliográficos
Autores principales:	Waki, Hironori, Yamauchi, Toshimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089000/ https://www.ncbi.nlm.nih.gov/pubmed/33460524 http://dx.doi.org/10.1111/jdi.13509

Ejemplares similares

Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
por: Dąbrowska, Anna Maria, et al.
Publicado: (2023)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

β(2 )adrenergic agonists in acute lung injury? The heart of the matter
por: Lee, Jae W
Publicado: (2009)

Repurposing the β(3)-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial
por: Balligand, Jean-Luc, et al.
Publicado: (2023)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Mirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
por: Bhide, Alka A, et al.
Publicado: (2012)

Agonist-Directed Desensitization of the β(2)-Adrenergic Receptor
por: Goral, Vasiliy, et al.
Publicado: (2011)

Pick the best of both glucose and lipid metabolism
por: Shimizu, Tatsunori, et al.
Publicado: (2022)

β3 Adrenergic Receptor Agonist Mirabegron Increases AQP2 and NKCC2 Urinary Excretion in OAB Patients: A Pleiotropic Effect of Interest for Patients with X-Linked Nephrogenic Diabetes Insipidus
por: Milano, Serena, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor
por: Warne, Tony, et al.
Publicado: (2011)

Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently
por: Chan, Chao-Shun, et al.
Publicado: (2022)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists
por: Hwang, Jinhee H, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Simulations of Biased Agonists in the β(2) Adrenergic Receptor with Accelerated Molecular Dynamics
por: Tikhonova, Irina G., et al.
Publicado: (2013)

β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
por: Zhao, Lin, et al.
Publicado: (2022)

β-agonists for ARDS: the dark side of adrenergic stimulation?
por: Thompson, B Taylor
Publicado: (2012)

Beta-Adrenergic Agonists
por: Barisione, Giovanni, et al.
Publicado: (2010)

Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders
por: Croen, Lisa A., et al.
Publicado: (2011)

The effect of adrenergic β(2) receptor agonist on paraplegia following clamping of abdominal aorta
por: Lee, Bok Y., et al.
Publicado: (2011)

Forearm vasodilator responses to a β‐adrenergic receptor agonist in premenopausal and postmenopausal women
por: Harvey, Ronee E., et al.
Publicado: (2014)

Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma
por: Jünemann, Anselm, et al.
Publicado: (2018)

Pharmacophore‐guided Virtual Screening to Identify New β(3)‐adrenergic Receptor Agonists
por: Ujiantari, Navista Sri Octa, et al.
Publicado: (2022)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Agonist binding by the β(2)-adrenergic receptor: an effect of receptor conformation on ligand association–dissociation characteristics
por: Plazinska, Anita, et al.
Publicado: (2015)

The Effects of Inhaled β-Adrenergic Agonists in Transient Tachypnea of the Newborn
por: Keleş, Esengul, et al.
Publicado: (2016)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Agemone mexicana flavanones; apposite inverse agonists of the β2-adrenergic receptor in asthma treatment
por: Eniafe, Gabriel O., et al.
Publicado: (2018)

Exacerbation of ozone-induced pulmonary and systemic effects by β(2)-adrenergic and/or glucocorticoid receptor agonist/s
por: Henriquez, Andres R., et al.
Publicado: (2019)

Inhibitory and Agonistic Autoantibodies Directed Against the β(2)-Adrenergic Receptor in Pseudoexfoliation Syndrome and Glaucoma
por: Hohberger, Bettina, et al.
Publicado: (2021)

Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice
por: Abu Eid, Sameer, et al.
Publicado: (2018)

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020)

Spinal β-adrenergic receptors’ activation increases the blood glucose level in mice
por: Sim, Yun-Beom, et al.
Publicado: (2017)

Better agonist for the opioid receptors
por: Badshah, Syed Lal, et al.
Publicado: (2018)

QSPR analysis of some agonists and antagonists of α-adrenergic receptors
por: Kawczak, Piotr, et al.
Publicado: (2014)

Adrenergic receptor agonists/hydrocortisone: Lack of efficacy: case report
Publicado: (2021)

Effect of β(2)-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting β(2)-adrenergic agonist response
por: Ambrose, Helen J, et al.
Publicado: (2012)

All roads lead to presynaptic calcium channel inhibition by the ghrelin receptor: Separate agonist-dependent and -independent signaling pathways
por: Weiss, Norbert, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ofbei85jv9kq98s7mk2vq4glrd